457 related articles for article (PubMed ID: 18848503)
41. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis.
Lees CW; Heys D; Ho GT; Noble CL; Shand AG; Mowat C; Boulton-Jones R; Williams A; Church N; Satsangi J; Arnott ID;
Aliment Pharmacol Ther; 2007 Aug; 26(3):411-9. PubMed ID: 17635376
[TBL] [Abstract][Full Text] [Related]
42. Infliximab in Hispanics: characterization of response to infliximab in an ethnic minority with Crohn's disease.
Sánchez JM; Maldonado JC; Torres EA; Rivera C
P R Health Sci J; 2005 Mar; 24(1):11-7. PubMed ID: 15895872
[TBL] [Abstract][Full Text] [Related]
43. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy.
D'Ovidio V; Vernia P; Gentile G; Capobianchi A; Marcheggiano A; Viscido A; Martino P; Caprilli R
J Clin Virol; 2008 Oct; 43(2):180-3. PubMed ID: 18614396
[TBL] [Abstract][Full Text] [Related]
44. Are patients with inflammatory bowel disease receiving optimal care?
Reddy SI; Friedman S; Telford JJ; Strate L; Ookubo R; Banks PA
Am J Gastroenterol; 2005 Jun; 100(6):1357-61. PubMed ID: 15929770
[TBL] [Abstract][Full Text] [Related]
45. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease.
Papadakis KA; Tung JK; Binder SW; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
Am J Gastroenterol; 2001 Jul; 96(7):2137-42. PubMed ID: 11467645
[TBL] [Abstract][Full Text] [Related]
46. Myocarditis and inflammatory bowel disease. A 16-year Danish nationwide cohort study.
Sørensen HT; Fonager KM
Dan Med Bull; 1997 Sep; 44(4):442-4. PubMed ID: 9377906
[TBL] [Abstract][Full Text] [Related]
47. Stability of infliximab dosing in inflammatory bowel disease: results from a multicenter US chart review.
Waters H; Vanderpoel J; McKenzie S; Lunacsek O; Franklin M; Lennert B; Goff J; Augustyn DH
J Med Econ; 2011; 14(4):397-402. PubMed ID: 21595522
[TBL] [Abstract][Full Text] [Related]
48. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye.
Beaugerie L; Sokol H; Seksik P
Dig Dis; 2009; 27(3):375-81. PubMed ID: 19786768
[TBL] [Abstract][Full Text] [Related]
49. Inflammatory bowel disease in relation to contact allergy: a patient-based study.
Engkilde K; Menné T; Johansen JD
Scand J Gastroenterol; 2007 May; 42(5):572-6. PubMed ID: 17454877
[TBL] [Abstract][Full Text] [Related]
50. Minimizing infliximab toxicity in the treatment of inflammatory bowel disease.
Orlando A; Mocciaro F; Civitavecchia G; Scimeca D; Cottone M
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S236-46. PubMed ID: 18598995
[TBL] [Abstract][Full Text] [Related]
51. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease.
Tabbara KF; Al-Hemidan AI
Am J Ophthalmol; 2008 Dec; 146(6):845-50.e1. PubMed ID: 18929351
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for opportunistic infections in patients with inflammatory bowel disease.
Toruner M; Loftus EV; Harmsen WS; Zinsmeister AR; Orenstein R; Sandborn WJ; Colombel JF; Egan LJ
Gastroenterology; 2008 Apr; 134(4):929-36. PubMed ID: 18294633
[TBL] [Abstract][Full Text] [Related]
53. Infliximab use in children and adolescents with inflammatory bowel disease.
de Ridder L; Benninga MA; Taminiau JA; Hommes DW; van Deventer SJ
J Pediatr Gastroenterol Nutr; 2007 Jul; 45(1):3-14. PubMed ID: 17592358
[TBL] [Abstract][Full Text] [Related]
54. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease.
Cottone M; Kohn A; Daperno M; Armuzzi A; Guidi L; D'Inca R; Bossa F; Angelucci E; Biancone L; Gionchetti P; Ardizzone S; Papi C; Fries W; Danese S; Riegler G; Cappello M; Castiglione F; Annese V; Orlando A
Clin Gastroenterol Hepatol; 2011 Jan; 9(1):30-5. PubMed ID: 20951835
[TBL] [Abstract][Full Text] [Related]
55. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis.
Bermejo F; Lopez-Sanroman A; Taxonera C; Gisbert JP; Pérez-Calle JL; Vera I; Menchén L; Martín-Arranz MD; Opio V; Carneros JA; Van-Domselaar M; Mendoza JL; Luna M; López P; Calvo M; Algaba A
Aliment Pharmacol Ther; 2008 Sep; 28(5):623-8. PubMed ID: 18513380
[TBL] [Abstract][Full Text] [Related]
56. Risk of arterial thrombotic events in inflammatory bowel disease.
Ha C; Magowan S; Accortt NA; Chen J; Stone CD
Am J Gastroenterol; 2009 Jun; 104(6):1445-51. PubMed ID: 19491858
[TBL] [Abstract][Full Text] [Related]
57. Mortality by medication use among patients with inflammatory bowel disease, 1996-2003.
Hutfless SM; Weng X; Liu L; Allison J; Herrinton LJ
Gastroenterology; 2007 Dec; 133(6):1779-86. PubMed ID: 18054550
[TBL] [Abstract][Full Text] [Related]
58. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up.
Gossec L; Le Henanff A; Breban M; Vignon E; Claudepierre P; Devauchelle V; Wendling D; Lespessailles E; Euller-Ziegler L; Sibilia J; Perdriger A; Alexandre C; Dougados M
Rheumatology (Oxford); 2006 Jul; 45(7):859-62. PubMed ID: 16436489
[TBL] [Abstract][Full Text] [Related]
59. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
Abraham NS; Richardson P; Castillo D; Kane SV
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
[TBL] [Abstract][Full Text] [Related]
60. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
Steenholdt C; Svenson M; Bendtzen K; Thomsen OØ; Brynskov J; Ainsworth MA
Aliment Pharmacol Ther; 2011 Jul; 34(1):51-8. PubMed ID: 21535447
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
